Is hepcidin-25 a predictor of atherosclerosis in hemodialysis patients?

Hemodialysis International

Volumn 20, Issue 2, 2016, Pages 191-197

  Kali, Alaaddin ^a   Yayar, Ozlem ^a   Erdogan, Bulent ^a   Eser, Baris ^a   Buyukbakkal, Mehmet ^a   Ercan, Zafer ^a   Merhametsiz, Ozgur ^a   Haspulat, Ayhan ^a   Gök Oğuz, Ebru ^a   Canbakan, Basol ^a   Ayli, Mehmet D ^a  

^a Dr Sami Ulus Women's and Children's Health Teaching and Research Hospital   (Turkey)

Author keywords

Anemia; Cardiovascular; Inflammation

Indexed keywords

ANTIANEMIC AGENT; C REACTIVE PROTEIN; FERRITIN; HEPCIDIN; HEPCIDIN 25; IRON; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ANEMIA; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; B SCAN; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; REAL TIME ECHOGRAPHY; ULTRASOUND TRANSDUCER; ADVERSE EFFECTS; BLOOD; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED;

ANEMIA; ATHEROSCLEROSIS; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; CROSS-SECTIONAL STUDIES; FEMALE; HEPCIDINS; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 84941702076     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/hdi.12355     Document Type: Article

References (30)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32(Suppl 3):S112-S119.
2. Stenvinkel P, Carrero JJ, Axelsson J, etal. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol. 2008; 3:505-521.
3. Nakanishi T, Hasuike Y, Otaki Y, etal. Hepcidin: Another culprit for complications in patients with chronic kidney disease? Nephrol Dial Transplant. 2011; 26:3092-3100.
4. Drueke T, Witko-Sarsat V, Massy Z, etal. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002; 106:2212-2217.
5. Park CH, Valore EV, Waring AJ, etal. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001; 276:7806-7810.
6. Pigeon C, Ilyin G, Courselaud B, etal. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001; 276:7811-7819.
7. Swinkels DW, Girelli D, Laarakkers C, etal. Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS ONE. 2008; 3:e2706.
8. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD. Am J Kidney Dis. 2010; 55:726-741.
9. Kroot JJ, Tjalsma H, Fleming RE, etal. Hepcidin in human iron disorders: Diagnostic implications. Clin Chem. 2011; 57:1650-1669.
10. Peters HPE, Laarakkers CMM, Swinkels DW, etal. Serum hepcidin- 25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant. 2010; 25:848-853.
11. Kato A, Tsuji T, Luo J, etal. Association of prohepcidin and hepcidin- 25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol. 2008; 28:115-121.
12. Kuragano T, Shimonaka Y, Kida A, etal. Determinants of hepcidin in patients on maintenance hemodialysis: Role of inflammation. Am J Nephrol. 2010; 31:534-540.
13. van der Weerd NC, Grooteman MP, Bots ML, etal. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS ONE. 2012; 7:e39783.
14. Weiss G, Theurl I, Eder S, etal. Serum hepcidin concentration in chronic haemodialysis patients: Associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest. 2009; 39:883-890.
15. Zaritsky J, Young B, Gales B, etal. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol. 2010; 5:1010-1014.
16. Kuragano T, Itoh K, Shimonaka Y, etal. Hepcidin as well as TNFalpha are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant. 2011; 26:2663-2667.
17. Valenti L, Dongiovanni P, Motta BM, etal. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol. 2011; 31:683-690.
18. Valenti L, Swinkels DW, Burdick L, etal. Serum ferritin levels are associated with vascular damage in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2011; 21:568-575.
19. de Groot E, Hovingh GK, Wiegman A, etal. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation. 2004; 109(23 Suppl 1):III33-III38.
20. Saeed O, Otsuka F, Polavarapu R, etal. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2012; 32:299-307.
21. Li JJ, Meng X, Si HP, etal. Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythrophagocytosis. Arterioscler Thromb Vasc Biol. 2012; 32:1158-1166.
22. Finn AV, Nakano M, Polavarapu R, etal. Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J Am Coll Cardiol. 2012; 59:166-177.
23. Galesloot TE, Holewijn S, Kiemeney LA, de Graaf J, Vermeulen SH, Swinkels DW. Serum hepcidin is associated with presence of plaque in postmenopausal women of a general population. Arterioscler Thromb Vasc Biol. 2014; 34:446-456.
24. Ulu SM, Yuksel S, Altuntas A, etal. Associations between serum hepcidin level, FGF-21 level and oxidative stress with arterial stiffness in CAPD patients. Int Urol Nephrol. 2014; 46:2409-2414.
25. van der Weerd NC, Grooteman MP, Bots ML, etal. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant. 2013; 28:3062-3071.
26. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009; 122:78-86.
27. Theurl I, Theurl M, Seifert M, etal. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood. 2008; 111:2392-2399.
28. Eleftheriadis T, Liakopoulos V, Antoniadi G, Kartsios C, Stefanidis I. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial. 2009; 22:70-77.
29. Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med. 2007; 232:1014-1020.
30. Sullivan JL. Iron in arterial plaque: Modifiable risk factor for atherosclerosis. Biochim Biophys Acta. 2009; 1790:718-723.